Keyphrases
Renal Cell Carcinoma
100%
Therapeutic Landscapes
100%
Immune Checkpoint Inhibitors
100%
Dark Ages
100%
Cell Death
66%
Metastatic Renal Cell Carcinoma (mRCC)
66%
Tyrosine Kinase Inhibitor
66%
Programmed Death-ligand 1 (PD-L1)
66%
Interferon-α (IFN-α)
33%
Treatment Response
33%
Clear Cell Renal Cell Carcinoma (ccRCC)
33%
Molecular Mechanism
33%
Clinical Trials
33%
Progression-free Survival
33%
Number of Patients
33%
Mammalian Target of Rapamycin (mTOR)
33%
Pathologic
33%
Interleukin-2
33%
Treatment Outcome
33%
Precision Medicine
33%
Therapeutic Potential
33%
Metastatic Disease
33%
Modern History
33%
Antiangiogenic
33%
Less Toxic
33%
Mechanism-based
33%
% Response
33%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
33%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
33%
Disease Control Rate
33%
Specific Treatment
33%
Targeted Therapeutics
33%
Oncological Treatment
33%
Diamond
33%
Kidney Tumor
33%
Renal Cell Carcinomas Subtypes
33%
Immuno-oncology
33%
Combined Administration
33%
Treatment Landscape
33%
Vascular Endothelial Growth Factor Receptor Inhibitor
33%
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Immune Checkpoint Inhibitor
75%
Cell Death
50%
Kidney Metastasis
50%
Programmed Death 1 Ligand 1
50%
Tyrosine-Kinase Inhibitor
50%
Interferon
25%
Treatment Response
25%
T Lymphocyte
25%
Clinical Trial
25%
Progression Free Survival
25%
Metastatic Carcinoma
25%
Disease
25%
Immunoglobulin
25%
Personalized Medicine
25%
Kidney Tumour
25%
Oncology
25%
Antiangiogenic
25%
Interleukin 2
25%
Vasculotropin Receptor 2
25%
Mammalian Target of Rapamycin Complex 1
25%
Targeted Therapeutic Agent
25%
Kidney Carcinoma
25%
Lanoteplase
25%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
100%
Immune Checkpoint Inhibitor
75%
Kidney Metastasis
50%
Protein Tyrosine Kinase Inhibitor
50%
Programmed Death 1 Ligand 1
50%
Disease
25%
Clinical Trial
25%
Progression Free Survival
25%
Interferon
25%
Immunoglobulin
25%
Mammalian Target of Rapamycin Complex 1
25%
Interleukin 2
25%
Metastasis
25%
Antiangiogenic
25%
Vasculotropin Receptor 2
25%
Kidney Tumour
25%
Lanoteplase
25%
Kidney Carcinoma
25%